OSLO (Reuters) - Norwegian bio-pharmaceutical firm Pronova Biopharma (PRON.OL: Quote, Profile, Research) is offering 105.9 million shares in connection with its planned listing on the Oslo bourse next month, valuing the firm at $1.25 billion to $1.57 billion.
